# Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment

> **NCT01298323** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 205 (actual)

## Conditions studied

- Locally Advanced or Metastatic Medullary Thyroid Cancer
- Medullary Thyroid Cancer

## Interventions

- **BEHAVIORAL:** Patient outreach
- **DRUG:** Vandetanib

## Key facts

- **NCT ID:** NCT01298323
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02-25
- **Primary completion:** 2013-04-26
- **Final completion:** 2025-03-13
- **Target enrollment:** 205 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01298323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01298323, "Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01298323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*